Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet …

Oct 18, 2021 · VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO ®. …

Jul 11, 2019 · Valneva at a glance. 3. Commercial vaccines. €153.7m. Total revenues in 2023. 3. Unique vaccine development programs. Integrated differentiated clinical and pre-clinical …

Mar 2, 2023 · Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the …

Jul 11, 2019 · Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical …

Dec 4, 2024 · Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Nov 10, 2023 · The U.S. Food and Drug Administration (FDA) has approved IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by …

Nov 7, 2024 · Valneva’s total revenues were €116.6 million in the nine months ended September 30, 2024 compared to €111.8 million in the nine months ended September 30, 2023. …

Jan 20, 2025 · Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® – Valneva [15] Valneva Reports Positive Pivotal Phase 3 Immunogenicity …

Jan 20, 2025 · Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million